The aim of this study is to elucidate the diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy for prostate cancer. We prospectively randomized 200 consecutive men into two groups to undergo systematic prostate biopsy. Overall positivity for cancer was similar (47% by transperineal and 53% by transrectal; P ¼ 0.480). However, in case with 'gray zone' PSA (from 4.1 to 10.0 ng/ml), significantly more cores were positive when approach was transperineal, especially among transition zone cores. Therefore, urologist preferences are sufficient for choosing an approach, except for a possible small advantage of transperineal biopsy when PSA is in gray zone.
Introduction
The systematic sextant prostate biopsy was introduced in 1989 for the diagnosis of localized prostate cancer by Hodge et al. 1 However, more recent studies have suggested that standard sextant biopsies may underestimate the incidence of cancer, with reported falsenegative rates of up to 31%. 2 Protocols proposed to improve the cancer detection rate have included increasing the number of specimen cores and sampling extended fields of the prostate. 3, 4 These studies indicated that useful sites to add to sextant biopsy included far lateral and anterior horn. However, Durkan et al. 3 reported that 31 of 164 cancer cases (19%) were not detected by sextant biopsies, and in 17 of these 31 cases, the transition zone (TZ) biopsies alone were positive. Thus, an optimal protocol has not yet been defined.
The studies described above all involved biopsy by a transrectal (TR) approach. In the United States, almost all urologists routinely perform prostate biopsy transrectally, while in Asian and European countries some institutions prefer transperineal (TP) prostate biopsy. [5] [6] [7] The latter approach has been incompletely investigated and, as with TR biopsy, an optimal technique or optimal number of biopsy cores is not established. At one time, the 'learning curve' for TP biopsy had been regarded as prohibitively long. However, TP insertion of materials for brachytherapy 8 into the prostate has increased familiarity with this approach.
We have performed systematic TP sextant biopsy guided by transrectal ultrasonography (TRUS) 9 since May 1992, and have performed 12-core biopsy using this approach since March 2000. We have found extended TP 12-core biopsy including four TZ cores to be more informative than TP 6-core biopsy. 5 Thus, some studies have found the TP approach to be more sensitive than the TR approach in cancer detection, and the TP approach now is being reevaluated in Europe and Asia. However, no prospective randomized study has compared cancer detection and complications between TP and TR approaches. Beginning in May 2003, we prospectively compared diagnostic efficacy and complications between TP and TR 12-core biopsy in patients assigned randomly to one of these procedures.
Patients and methods
Between May 2003 and September 2004, we prospectively compared 200 consecutive men divided randomly into two groups. Systematic biopsy of the prostate was performed with indications including prostate-specific antigen (PSA) over 4 ng/ml and/or abnormal findings by digital rectal examination (DRE) or TRUS. The randomly assigned groups of 100 patients underwent TP 12-core biopsy or TR 12-core biopsy. All procedures were guided by TRUS.
Patient characteristics are shown in Table 1 . No significant differences were found between TP and TR groups in mean age, the mean PSA, the mean prostate volume, mean PSA density (PSAD; PSA divided by prostate volume), or DRE or TRUS findings. All 200 men had not previously undergone prostate biopsy.
As preparation for both procedures, an enema was given on the morning of the biopsy, and antibiotic coverage with 300 mg of levofloxacin was administered for 1 day. TP biopsy was guided by TRUS (SSD-2000; Aloka, Tokyo, Japan) and performed under saddle blockade with 0.5% bupivacaine. A TR linear probe (UST-672-5/7.5, 7.5 MHz; Aloka) with an attachment for needle guidance was used for this procedure. All patients were placed in the lithotomy position, and underwent evaluation before biopsy with DRE and TRUS. An 18-gauge Monopty biopsy needle (Bard, Delran, NJ, USA) was used. Cores were obtained from the peripheral zone (PZ) at six sites, from the TZ in four and from the apex in two (Figure 1a ). This represents addition of two PZ sites at far lateral side, two TZ sites ventrally and two apical cores to the standard sextant cores described by Saitoh et al. 10 TR biopsy was carried out using the same ultrasonographic guidance under caudal blockade with 1% lidocaine. A TR radial probe (UST-670P-5, 5 MHz, Aloka) with a needle-guidance attachment was used for this procedure. We obtained six PZ, four TZ and two apical cores ( Figure 1b ).
Using PSA, PSAD, DRE and TRUS to stratify patients, we examined the cancer case detection rate (number of cancer patients/total numbers of patients). We also examined cancer core detection rates (number of cancer-positive cores/total cores) according to biopsy sites.
Complications associated with biopsy were categorized as macrohematuria, high fever (438.51C), urinary retention, hematospermia, rectal bleeding, vasovagal episode and post-dural puncture headache during the following 4 weeks. Major complications were defined as those requiring additional in-patient treatment.
Student's t-test was used to compare continuous variables between the two groups. w 2 or Fisher's exact probability tests were used for categorical variables. Statistical significance was accepted in our study when P-value was below 0.05.
This study was conducted with a proper Institutional Review Board approve and patient consent.
Results
The overall cancer case detection rate did not differ significantly between groups (Table 2 ; 47 of 100 cases for TP biopsy and 53 of 100 for TR biopsy; P ¼ 0.480). Even after stratification by PSA, PSAD, DRE findings or TRUS findings, we could not detect differences in cancer detection between TP and TR. In cases with PSA between 4.1 and 10.0 ng/ml, PSAD between 0.10 and 0.20, negative DRE and negative TRUS (tumors without apparent local advancement), cancer detection by TP and TR was 36.1 vs 35.1%, 17.2 vs 29.0%, 41.7 vs 43.1%, and 40.3 vs 47.4%, respectively. These results demonstrated no significant difference between TP and TR biopsy.
We examined differences in cancer core detection rate for various core locations (Table 3 ). Core positivity rates at PZ, TZ, the apex and all sites compared between TP and TR were 15.3 and 17.5%, 15.3 and 18.0%, 12.0 and 18.0%, and 14.7 and 17.8%, respectively. Overall positivity of cores was significantly higher in TR than in TP. However, when we examined only cases with 'gray zone' PSA (from 4.1 to 10.0 ng/ml), the core positivity rate for TP was significantly higher than that for TR. In paticular, TP showed a higher positivity rate in cores from the TZ. Table 4 compares complications between TP and TR, with 19 and 20 complications, respectively, affecting 18 TP cases and 18 TR cases. One patient with TP had two complications (macrohematuria and post-dural puncture headache), whereas one patient with TR had three complications (macrohematuria, high fever and urinary retention). No differences in rate of any complication Comparison between transperineal and rectal biopsy A Takenaka et al were evident between TP and TR. Only one patient with TP and two with TR had major complications.
Discussion
To the best of our knowledge, this is the first prospective randomized study comparing diagnostic efficacy and complications between systematic TP and TR prostate biopsy. Cancer detection rate was 47% for TP and 53% for TR (no significant difference). As for complications, 19 and 20 affected 18 TP patients and 18 TR patients, respectively. Thus, diagnostic efficacy and complication rate were nearly equal between TP and TR biopsy. Since initial description of the Hodge protocol, little has been reported about TP biopsy. However, few studies have reported notable success in cancer diagnosis with extended biopsy using this technique. Kojima et al. 7 retrospectively reported usefulness of TP systematic 12-core biopsy in comparison to 6-core biopsy. In a prospective study, our group demonstrated that cancer detection improved significantly to 20.4%, in TP extended 12-core biopsy, including four TZ cores, compared with 6-core biopsy. 5 Emiliozzi et al. 11 advocated TP 12-core biopsy using a fan technique, based on a cancer detection rate of 51% (72/141), and even a rate of 45% when PSA ranged from 4.1 to 10.0 ng/ml, this represents greater success than previously reported rates using TR approaches. However, no prospective randomized studies have been compared the diagnostic efficacy and complications between TP and TR biopsy. We have found two retrospective, non-randomized comparisons of TP and TR biopsy. Vis et al. 12 sought to detect prostate cancer foci in experimental TR and TP biopsy specimens taken from 40 radical prostatectomy specimens obtained after cancer had been confirmed by TRUS-guided sextant TR biopsy. Thirty-three cancers (82.5%) were redetected by the TP approach, while 29 (72.5%) were redetected by the TR approach. TP biopsy showed higher sensitivity in cancer detection than TR in minimal (55.5 vs 45.5%) and moderate (95.8 vs 79.2%) disease. The TP approach may be particularly useful in detecting apically located tumors, since 92.6% of these were redetected by TP compared with 81.5% by TR. On the other hand, the TP method missed two cancers located at the prostatic base. Emiliozzi et al. 13 performed prostate biopsy with six TP cores plus six TR cores in a prospective study. Of the 43 who were diagnosed cancer, 41 (95%) were detected by the TP approach and 34 (79%) by the TR approach (P ¼ 0.012). In sextant biopsy, then, TP seemed statistically superior to TR for prostate cancer detection. We believe that the present result differed from those of above two studies because of differences in the number of cores. We believe that obtaining more cores reduced the difference in cancer detection rate between the two approaches. Accordingly, the TP approach might be preferable for diagnosis of early prostate cancer in situations where the number of cores is limited to six.
We presently found that in patients with 'gray-zone' PSA values, significantly more TZ cores were positive with the TP approach than with TR (P ¼ 0.045). A previous study of 'saturation' biopsy found that the TP approach enhanced identification of TZ cancers. 2 used a TR approach to obtain an average of 22.5 cores per patient, the cancer was located entirely within the TZ in only 6% of cancer cases. Some reports based on prostatectomy specimens described TZ cancers as accounting for 18-24% of cases, 15, 16 while wholly TZ cancers accounted for 2-10%. 17, 18 However, most of these cases were diagnosed by standard sextant biopsy using a TR approach. Such mapping results would not be equivalent to natural incidence. Mapping of prostatectomy specimens from saturation TP biopsy, which gives results equivalent to natural cancer incidence, demonstrated eight cancers limited to the TZ in 30 prostatectomy specimens (27%).
14 For detecting TZ cancers in patients with gray-zone PSA, our TP biopsy, including four TZ cores, seems to be more informative than TR biopsy.
The anesthesia in TP biopsy has been incompletely discussed. But, it is evident that everyone uses some kind of anesthesia in TP biopsy without exception, differently from in TR. Emiliozzi et al.
11 used local anesthesia with mepivacaine, Pinkstaff et al.
14 used general anesthesia, and Satoh et al. 21 used caudal block. In many institutes in Japan, TP biopsy is performed in an in-patient setting, and spinal or saddle blockade are sometimes chosen. 21 Previously we performed TP biopsy with local anesthesia, but the efficacy was not enough. So we changed to saddle blockage.
Complications of TP biopsy have received little attention in the literature. In a study of TP saturation biopsy, 2 urinary retention was the only complication occurring in 11%. In the present study, the most frequent complication of the TP approach was macrohematuria, showing no significant difference in frequency from the TR approach (TP, 11%; TR, 12%). No significant difference between TP and TR was found for other complications. Rare but life-threatening complications reported for prostate biopsy include urosepsis (2.2%) 19 and rectal bleeding (0.9%). 20 Of these, rectal bleeding does not occur with TP. Critical complications therefore should be rarer in TP than in TR. Since TP procedures have become familiar in carrying out prostatic brachytherapy, 10 the TP approach no longer presents disadvantages in complications or complexity compared with TR.
As we described above, TR and TP biopsy were equivalent in the cancer detection rate and the complication. So, we cannot show any scientific data to change TR to TP technique. Generally speaking, the merit of TR biopsy is simplicity including the technique of anesthesia, and the demerits are infection and rectal bleeding. On the other hand, the merit of TP method is low frequency of infection, and the demerit is complexity. Therefore, urologist preferences are sufficient for choosing an approach, except for a possible small advantage of TP biopsy when PSA is in gray zone.
Conclusion
This first prospective randomized comparison between TP and TR 12-core biopsy showed no significant differences in cancer detection rate (47 vs 53%) or complication rate (18 vs 18%). However, in gray-zone PSA cases, more TZ cores were positive with the TP approach than with TR. Urologists should have free choice of either approach, especially when PSA is higher.
